Arkolith/Insider Trading/TRIL/Form 4

Uger Robert

Chief Scientific OfficerTrillium Therapeutics Inc. (TRIL) · full profile →Form 4 · filed May 11, 2021
Net Selling
Open-Market Buys
$0
Open-Market Sells
$34K
Net Open-Market Flow
-$34K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 7, 2021Sell(S)4K$9.30$34K0
May 7, 2021Option exercise(M)4K$0.31$1K4K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 7, 2021Option exercise(M)4K—$0109K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-21-004390) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML